Imexpharm Statistics

Total Valuation

Imexpharm has a market cap or net worth of VND 7.69 trillion. The enterprise value is 7.52 trillion.

Market Cap	7.69T
Enterprise Value	7.52T

Important Dates

The next estimated earnings date is Thursday, October 17, 2024.

Earnings Date	Oct 17, 2024
Ex-Dividend Date	Jul 11, 2024

Share Statistics

Imexpharm has 154.01 million shares outstanding. The number of shares has decreased by -2.93% in one year.

Shares Outstanding	154.01M
Shares Change (YoY)	-2.93%
Shares Change (QoQ)	+16.97%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.64%
Float	54.17M

Valuation Ratios

The trailing PE ratio is 33.84 and the forward PE ratio is 24.88.

PE Ratio	33.84
Forward PE	24.88
PS Ratio	3.69
PB Ratio	3.70
P/FCF Ratio	449.19
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.50, with an EV/FCF ratio of 439.66.

EV / Earnings	33.12
EV / Sales	3.61
EV / EBITDA	16.50
EV / EBIT	21.38
EV / FCF	439.66

Financial Position

The company has a current ratio of 3.18, with a Debt / Equity ratio of 0.05.

Current Ratio	3.18
Quick Ratio	1.40
Debt / Equity	0.05
Debt / EBITDA	0.21
Debt / FCF	5.64
Interest Coverage	75.77

Financial Efficiency

Return on equity (ROE) is 13.43% and return on invested capital (ROIC) is 10.23%.

Return on Equity (ROE)	13.43%
Return on Assets (ROA)	8.75%
Return on Capital (ROIC)	10.23%
Revenue Per Employee	1.45B
Profits Per Employee	157.83M
Employee Count	1,415
Asset Turnover	0.83
Inventory Turnover	1.64

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +65.14% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+65.14%
50-Day Moving Average	45,267.00
200-Day Moving Average	34,421.52
Relative Strength Index (RSI)	57.81
Average Volume (20 Days)	225,030

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Imexpharm had revenue of VND 2.08 trillion and earned 227.12 billion in profits. Earnings per share was 1,474.62.

Revenue	2.08T
Gross Profit	960.89B
Operating Income	351.76B
Pretax Income	338.97B
Net Income	227.12B
EBITDA	455.98B
EBIT	351.76B
Earnings Per Share (EPS)	1,474.62

Full Income Statement

Balance Sheet

The company has 259.52 billion in cash and 96.41 billion in debt, giving a net cash position of 163.11 billion or 1,059.08 per share.

Cash & Cash Equivalents	259.52B
Total Debt	96.41B
Net Cash	163.11B
Net Cash Per Share	1,059.08
Equity (Book Value)	2.08T
Book Value Per Share	13,490.43
Working Capital	931.95B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 68.10 billion and capital expenditures -51.00 billion, giving a free cash flow of 17.11 billion.

Operating Cash Flow	68.10B
Capital Expenditures	-51.00B
Free Cash Flow	17.11B
FCF Per Share	111.09

Full Cash Flow Statement

Margins

Gross margin is 46.12%, with operating and profit margins of 16.88% and 12.95%.

Gross Margin	46.12%
Operating Margin	16.88%
Pretax Margin	16.27%
Profit Margin	12.95%
EBITDA Margin	21.89%
EBIT Margin	16.88%
FCF Margin	0.82%

Dividends & Yields

This stock pays an annual dividend of 454.55, which amounts to a dividend yield of 0.90%.

Dividend Per Share	454.55
Dividend Yield	0.90%
Dividend Growth (YoY)	10.00%
Years of Dividend Growth	n/a
Payout Ratio	24.70%
Buyback Yield	2.93%
Shareholder Yield	3.83%
Earnings Yield	2.96%
FCF Yield	0.22%

Dividend Details

Stock Splits

The last stock split was on September 17, 2024. It was a forward split with a ratio of 2.

Last Split Date	Sep 17, 2024
Split Type	Forward
Split Ratio	2

Scores

Imexpharm has an Altman Z-Score of 8.53.

Altman Z-Score	8.53
Piotroski F-Score	n/a